Canada markets closed

InnoCan Pharma Corporation (INNO.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.3000-0.0100 (-3.23%)
At close: 10:38AM EST
Full screen
Previous Close0.3100
Open0.3000
Bid0.2900 x N/A
Ask0.3100 x N/A
Day's Range0.3000 - 0.3000
52 Week Range0.1950 - 0.8000
Volume45,312
Avg. Volume43,182
Market Cap74.886M
Beta (5Y Monthly)3.66
PE Ratio (TTM)N/A
EPS (TTM)-0.0320
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce that it has signed a consulting agreement with Benitz Consulting LLC ("Benitz Consulting") to assist the Company's commercialization of IP in the veterinary field. The principal of Benitz Consulting

  • Newsfile

    Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its financial results for the three and nine months ended September 30, 2022. "We delivered encouraging results in the third quarter, with revenue growth and ar

  • Newsfile

    Mr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 18, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the addition of Givi Topchishvili, to Innocan's Advisory Committee, as a business strategy adviser, focused on commercializing of healthcare innovations. Giv